Could Albuminuria Be an Overlooked Marker of Thrombotic Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Xiu Hong Yang et al, adding:
”Could albuminuria be an overlooked marker of thrombotic risk?
We usually think of the urine albumin-to-creatinine ratio (UACR) as a kidney or cardiovascular marker.
But what if it also reflects systemic thrombotic vulnerability?
A new prospective RPTH study of 419,282 UK Biobank participants examined the relationship between albuminuria and future arterial thromboembolism (ATE) and pulmonary embolism (PE).
Here’s the key signal:
- Moderate albuminuria (UACR 3–30 mg/mmol) increased ATE risk
- Severe albuminuria (>30 mg/mmol) increased the risk of both ATE and c
- Risk intensified further with reduced kidney function or low serum albumin
What’s changing under the hood:
- Albuminuria reflects endothelial dysfunction and vascular injury
- Associated with platelet activation and hypercoagulability
- Linked to inflammatory pathways (CRP, VWF, ADAMTS13)
- Suggests a systemic prothrombotic state – not just kidney disease
(Figures 1–3 show dose-dependent increases in thrombotic risk with rising UACR)
Translation:
Albuminuria may not simply mark renal injury; it may identify patients with heightened endothelial and thrombotic dysfunction.
Big questions for the field:
- Should UACR be incorporated into thrombosis risk assessment?
- Is albuminuria a mediator of thrombosis – or a marker of systemic vascular injury?
- Could aggressive treatment of albuminuria reduce thromboembolic events?”
Title: Urine albumin-to-creatinine ratio and risks of incident arterial thromboembolism and pulmonary embolism among adults—a prospective cohort study
Authors: Xiu Hong Yang, Yao Liu, Zhen Xing Zhang, Yi Jun Lu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye, Xiao Li Zhang

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales